The University of Chicago Header Logo

Connection

Ayman Al-Hendy to Leiomyoma

Back to Details
This is a "connection" page, showing publications Ayman Al-Hendy has written about Leiomyoma.
Ayman Al-Hendy
Connection Strength
50.550
Leiomyoma
  1. A plain language summary describing changes in pain associated with uterine fibroids among women receiving relugolix combination therapy. Pain Manag. 2024 Sep; 14(9):469-476.
    View in: PubMed
    Score: 0.732
  2. Uterine fibroids: current research on novel drug targets and innovative therapeutic strategies. Expert Opin Ther Targets. 2024 Aug; 28(8):669-687.
    View in: PubMed
    Score: 0.721
  3. Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary. J Comp Eff Res. 2024 08; 13(8):e230194.
    View in: PubMed
    Score: 0.715
  4. Altered extracellular matrix-related pathways accelerate the transition from normal to prefibroid myometrium in Black women. Am J Obstet Gynecol. 2024 Sep; 231(3):324.e1-324.e12.
    View in: PubMed
    Score: 0.711
  5. Quality of life improvements in women with uterine fibroids treated with relugolix combination therapy during the LIBERTY long-term extension study: A descriptive subgroup analysis in women with anemia at baseline. Int J Gynaecol Obstet. 2024 May; 165(2):431-441.
    View in: PubMed
    Score: 0.704
  6. Empowering Strategies for Lifestyle Interventions, Diet Modifications, and Environmental Practices for Uterine Fibroid Prevention; Unveiling the LIFE UP Awareness. Nutrients. 2024 Mar 12; 16(6).
    View in: PubMed
    Score: 0.701
  7. Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases-Focus on Epigenetic Mechanisms. Nutrients. 2024 Feb 17; 16(4).
    View in: PubMed
    Score: 0.697
  8. Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) - protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids. BMJ Open. 2024 01 12; 14(1):e078989.
    View in: PubMed
    Score: 0.693
  9. Bromodomain-Containing Protein 9 Regulates Signaling Pathways and Reprograms the Epigenome in Immortalized Human Uterine Fibroid Cells. Int J Mol Sci. 2024 Jan 11; 25(2).
    View in: PubMed
    Score: 0.693
  10. Survivin-Sodium Iodide Symporter Reporter as a Non-Invasive Diagnostic Marker to Differentiate Uterine Leiomyosarcoma from Leiomyoma. Cells. 2023 12 13; 12(24).
    View in: PubMed
    Score: 0.689
  11. Evidence-Based Approach for Secondary Prevention of Uterine Fibroids (The ESCAPE Approach). Int J Mol Sci. 2023 Nov 04; 24(21).
    View in: PubMed
    Score: 0.684
  12. Current and Emerging Treatment Options for Uterine Fibroids. Drugs. 2023 Dec; 83(18):1649-1675.
    View in: PubMed
    Score: 0.684
  13. Endocrine-disrupting chemicals and epigenetic reprogramming in developmental origin of uterine fibroids. Sci Prog. 2023 Oct-Dec; 106(4):368504231215601.
    View in: PubMed
    Score: 0.679
  14. The combination of natural compounds Crila and epigallocatechin gallate showed enhanced antiproliferative effects on human uterine fibroid cells compared with single treatments. F S Sci. 2023 11; 4(4):341-349.
    View in: PubMed
    Score: 0.678
  15. TGFß signaling links early life endocrine-disrupting chemicals exposure to suppression of nucleotide excision repair in rat myometrial stem cells. Cell Mol Life Sci. 2023 Sep 09; 80(10):288.
    View in: PubMed
    Score: 0.676
  16. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2023 12; 229(6):662.e1-662.e25.
    View in: PubMed
    Score: 0.676
  17. Developmental reprogramming of myometrial stem cells by endocrine disruptor linking to risk of uterine fibroids. Cell Mol Life Sci. 2023 Aug 31; 80(9):274.
    View in: PubMed
    Score: 0.675
  18. GnRH agonists and antagonists in therapy of symptomatic uterine fibroids - current roles and future perspectives. Expert Opin Pharmacother. 2023 Sep-Dec; 24(16):1799-1809.
    View in: PubMed
    Score: 0.674
  19. Uterine Fibroids: A Podcast on Patient and Physician Perspectives on Medical Management and a New Medical Therapy (Relugolix Combination Therapy). Adv Ther. 2023 10; 40(10):4127-4133.
    View in: PubMed
    Score: 0.673
  20. A plain language summary of the long-term relugolix combination therapy study for uterine fibroids. J Comp Eff Res. 2023 08; 12(8):e230069.
    View in: PubMed
    Score: 0.670
  21. Epigenetic Modulation of Inflammatory Pathways in Myometrial Stem Cells and Risk of Uterine Fibroids. Int J Mol Sci. 2023 Jul 19; 24(14).
    View in: PubMed
    Score: 0.670
  22. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial. F S Sci. 2023 Nov; 4(4):317-326.
    View in: PubMed
    Score: 0.669
  23. A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies. Pain Manag. 2023 Apr; 13(4):205-211.
    View in: PubMed
    Score: 0.662
  24. EZH2 activates Wnt/ß-catenin signaling in human uterine fibroids, which is inhibited by the natural compound methyl jasmonate. F S Sci. 2023 08; 4(3):239-256.
    View in: PubMed
    Score: 0.661
  25. Progesterone Signaling and Uterine Fibroid Pathogenesis; Molecular Mechanisms and Potential Therapeutics. Cells. 2023 04 09; 12(8).
    View in: PubMed
    Score: 0.657
  26. Update on the Role and Regulatory Mechanism of Extracellular Matrix in the Pathogenesis of Uterine Fibroids. Int J Mol Sci. 2023 Mar 17; 24(6).
    View in: PubMed
    Score: 0.654
  27. Gene Expression Profile of Uterine Leiomyoma from Women Exposed to Different Air Pollution Levels in Metropolitan Cities of Sao Paulo, Brazil. Int J Mol Sci. 2023 Jan 26; 24(3).
    View in: PubMed
    Score: 0.648
  28. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials. Am J Obstet Gynecol. 2023 03; 228(3):320.e1-320.e11.
    View in: PubMed
    Score: 0.639
  29. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas. Obstet Gynecol. 2022 12 01; 140(6):920-930.
    View in: PubMed
    Score: 0.638
  30. Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocr Rev. 2022 07 13; 43(4):678-719.
    View in: PubMed
    Score: 0.624
  31. The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma. Cells. 2022 07 10; 11(14).
    View in: PubMed
    Score: 0.624
  32. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials. Obstet Gynecol. 2022 06 01; 139(6):1070-1081.
    View in: PubMed
    Score: 0.616
  33. Epigenetic Regulation in Uterine Fibroids-The Role of Ten-Eleven Translocation Enzymes and Their Potential Therapeutic Application. Int J Mol Sci. 2022 Feb 28; 23(5).
    View in: PubMed
    Score: 0.608
  34. An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Opin Pharmacother. 2022 Mar; 23(4):421-429.
    View in: PubMed
    Score: 0.604
  35. Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids. Expert Opin Drug Saf. 2022 Apr; 21(4):477-486.
    View in: PubMed
    Score: 0.594
  36. Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids. J Womens Health (Larchmt). 2022 05; 31(5):698-705.
    View in: PubMed
    Score: 0.591
  37. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. N Engl J Med. 2021 02 18; 384(7):630-642.
    View in: PubMed
    Score: 0.567
  38. The Significance of Measuring Vitamin D Serum Levels in Women with Uterine Fibroids. Reprod Sci. 2021 08; 28(8):2098-2109.
    View in: PubMed
    Score: 0.555
  39. Vitamins and Uterine Fibroids: Current Data on Pathophysiology and Possible Clinical Relevance. Int J Mol Sci. 2020 Aug 01; 21(15).
    View in: PubMed
    Score: 0.545
  40. Evolving role of microRNAs in uterine fibroid pathogenesis: filling the gap! Fertil Steril. 2020 06; 113(6):1167-1168.
    View in: PubMed
    Score: 0.539
  41. Molecular Bio-Imaging Probe for Non-Invasive Differentiation Between Human Leiomyoma Versus Leiomyosarcoma. Reprod Sci. 2020 02; 27(2):644-654.
    View in: PubMed
    Score: 0.525
  42. Alcohol Consumption and Risk of Uterine Fibroids. Curr Mol Med. 2020; 20(4):247-258.
    View in: PubMed
    Score: 0.524
  43. Vitamin D and uterine fibroids: preclinical evidence is in; time for an overdue clinical study! Fertil Steril. 2020 01; 113(1):89-90.
    View in: PubMed
    Score: 0.524
  44. Simvastatin and uterine fibroids: opportunity for a novel therapeutic option. Fertil Steril. 2018 12; 110(7):1272-1273.
    View in: PubMed
    Score: 0.486
  45. Endocrine disruptor exposure during development increases incidence of uterine fibroids by altering DNA repair in myometrial stem cells. Biol Reprod. 2018 10 01; 99(4):735-748.
    View in: PubMed
    Score: 0.480
  46. Uterine fibroid therapy: the pharmacokinetic considerations. Expert Opin Drug Metab Toxicol. 2018 Sep; 14(9):887-889.
    View in: PubMed
    Score: 0.475
  47. Expanding upon the Human Myometrial Stem Cell Hypothesis and the Role of Race, Hormones, Age, and Parity in a Profibroid Environment. Am J Pathol. 2018 10; 188(10):2293-2306.
    View in: PubMed
    Score: 0.475
  48. Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2018 03; 131(3):431-439.
    View in: PubMed
    Score: 0.461
  49. Successes and failures of uterine leiomyoma drug discovery. Expert Opin Drug Discov. 2018 02; 13(2):169-177.
    View in: PubMed
    Score: 0.455
  50. Uterine Leiomyoma: New Perspectives on an Old Disease. Semin Reprod Med. 2017 11; 35(6):471-472.
    View in: PubMed
    Score: 0.451
  51. Uterine Fibroids: Burden and Unmet Medical Need. Semin Reprod Med. 2017 11; 35(6):473-480.
    View in: PubMed
    Score: 0.451
  52. Origin of Uterine Fibroids: Conversion of Myometrial Stem Cells to Tumor-Initiating Cells. Semin Reprod Med. 2017 11; 35(6):481-486.
    View in: PubMed
    Score: 0.451
  53. Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids. Biol Reprod. 2017 Sep 01; 97(3):337-352.
    View in: PubMed
    Score: 0.446
  54. Silencing Med12 Gene Reduces Proliferation of Human Leiomyoma Cells Mediated via Wnt/ß-Catenin Signaling Pathway. Endocrinology. 2017 03 01; 158(3):592-603.
    View in: PubMed
    Score: 0.430
  55. Estrogen Receptors and Signaling in Fibroids: Role in Pathobiology and Therapeutic Implications. Reprod Sci. 2017 09; 24(9):1235-1244.
    View in: PubMed
    Score: 0.422
  56. Developmental Exposure to Endocrine Disruptors Expands Murine Myometrial Stem Cell Compartment as a Prerequisite to Leiomyoma Tumorigenesis. Stem Cells. 2017 03; 35(3):666-678.
    View in: PubMed
    Score: 0.421
  57. Hypovitaminosis D and high serum transforming growth factor beta-3: important biomarkers for uterine fibroids risk. Fertil Steril. 2016 12; 106(7):1648-1649.
    View in: PubMed
    Score: 0.420
  58. Identification of Polycomb Group Protein EZH2-Mediated DNA Mismatch Repair Gene MSH2 in Human Uterine Fibroids. Reprod Sci. 2016 10; 23(10):1314-25.
    View in: PubMed
    Score: 0.404
  59. Magnetic nanoparticles as a new approach to improve the efficacy of gene therapy against differentiated human uterine fibroid cells and tumor-initiating stem cells. Fertil Steril. 2016 06; 105(6):1638-1648.e8.
    View in: PubMed
    Score: 0.403
  60. The Polycomb Group Protein EZH2 Impairs DNA Damage Repair Gene Expression in Human Uterine Fibroids. Biol Reprod. 2016 Mar; 94(3):69.
    View in: PubMed
    Score: 0.401
  61. Targeted Adenoviral Vector Demonstrates Enhanced Efficacy for In Vivo Gene Therapy of Uterine Leiomyoma. Reprod Sci. 2016 Apr; 23(4):464-74.
    View in: PubMed
    Score: 0.400
  62. Vitamin D3 Inhibits Wnt/ß-Catenin and mTOR Signaling Pathways in Human Uterine Fibroid Cells. J Clin Endocrinol Metab. 2016 04; 101(4):1542-51.
    View in: PubMed
    Score: 0.399
  63. The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development. Reprod Sci. 2016 Feb; 23(2):163-75.
    View in: PubMed
    Score: 0.379
  64. 1,25-dihydroxyvitamin D3 regulates expression of sex steroid receptors in human uterine fibroid cells. J Clin Endocrinol Metab. 2015 Apr; 100(4):E572-82.
    View in: PubMed
    Score: 0.372
  65. Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids. Mol Genet Genomics. 2015 Apr; 290(2):505-11.
    View in: PubMed
    Score: 0.365
  66. Can vitamin D reduce the risk of uterine fibroids? Womens Health (Lond). 2014 Jul; 10(4):353-8.
    View in: PubMed
    Score: 0.358
  67. Green tea extract inhibition of human leiomyoma cell proliferation is mediated via catechol-O-methyltransferase. Gynecol Obstet Invest. 2014; 78(2):109-18.
    View in: PubMed
    Score: 0.357
  68. Paricalcitol, a vitamin d receptor activator, inhibits tumor formation in a murine model of uterine fibroids. Reprod Sci. 2014 Sep; 21(9):1108-19.
    View in: PubMed
    Score: 0.356
  69. 1,25-dihydroxyvitamin d3 reduces extracellular matrix-associated protein expression in human uterine fibroid cells. Biol Reprod. 2013 Dec; 89(6):150.
    View in: PubMed
    Score: 0.345
  70. Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma. Semin Reprod Med. 2013 Sep; 31(5):370-9.
    View in: PubMed
    Score: 0.336
  71. Targeting adenoviral vectors for enhanced gene therapy of uterine leiomyomas. Hum Reprod. 2013 Sep; 28(9):2398-406.
    View in: PubMed
    Score: 0.334
  72. Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells. Hum Reprod. 2013 Sep; 28(9):2407-16.
    View in: PubMed
    Score: 0.334
  73. 1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model. Biol Reprod. 2012 Apr; 86(4):116.
    View in: PubMed
    Score: 0.307
  74. Medical treatment of uterine leiomyoma. Reprod Sci. 2012 Apr; 19(4):339-53.
    View in: PubMed
    Score: 0.304
  75. Adipocytes enhance the proliferation of human leiomyoma cells via TNF-a proinflammatory cytokine. Reprod Sci. 2011 Dec; 18(12):1186-92.
    View in: PubMed
    Score: 0.299
  76. Towards non-surgical therapy for uterine fibroids: catechol-O-methyl transferase inhibitor shrinks uterine fibroid lesions in the Eker rat model. Hum Reprod. 2011 Nov; 26(11):3008-18.
    View in: PubMed
    Score: 0.294
  77. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertil Steril. 2011 Jan; 95(1):247-53.
    View in: PubMed
    Score: 0.274
  78. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am J Obstet Gynecol. 2010 Mar; 202(3):289.e1-9.
    View in: PubMed
    Score: 0.263
  79. Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertil Steril. 2010 Oct; 94(5):1887-93.
    View in: PubMed
    Score: 0.258
  80. Towards fibroid gene therapy: adenovirus-mediated delivery of herpes simplex virus 1 thymidine kinase gene/ganciclovir shrinks uterine leiomyoma in the Eker rat model. Gynecol Obstet Invest. 2009; 68(1):19-32.
    View in: PubMed
    Score: 0.248
  81. Gene therapy targeting leiomyoma: adenovirus-mediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model. Fertil Steril. 2010 Jan; 93(1):239-50.
    View in: PubMed
    Score: 0.245
  82. Memy I: a novel murine model for uterine leiomyoma using adenovirus-enhanced human fibroid explants in severe combined immune deficiency mice. Am J Obstet Gynecol. 2008 Aug; 199(2):156.e1-8.
    View in: PubMed
    Score: 0.234
  83. Molecular genetics and racial disparities of uterine leiomyomas. Best Pract Res Clin Obstet Gynaecol. 2008 Aug; 22(4):589-601.
    View in: PubMed
    Score: 0.232
  84. Toward gene therapy of uterine fibroids: targeting modified adenovirus to human leiomyoma cells. Hum Reprod. 2008 Mar; 23(3):514-24.
    View in: PubMed
    Score: 0.228
  85. Adenovirus-mediated delivery of a dominant-negative estrogen receptor gene in uterine leiomyoma cells abrogates estrogen- and progesterone-regulated gene expression. J Clin Endocrinol Metab. 2007 Oct; 92(10):3949-57.
    View in: PubMed
    Score: 0.221
  86. Estrogen metabolite 2-methoxyestradiol induces apoptosis and inhibits cell proliferation and collagen production in rat and human leiomyoma cells: a potential medicinal treatment for uterine fibroids. J Soc Gynecol Investig. 2006 Dec; 13(8):542-50.
    View in: PubMed
    Score: 0.211
  87. Gene therapy of uterine leiomyoma: adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir treatment inhibits growth of human and rat leiomyoma cells in vitro and in a nude mouse model. Gynecol Obstet Invest. 2007; 63(2):61-70.
    View in: PubMed
    Score: 0.208
  88. Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril. 2006 Sep; 86(3):686-93.
    View in: PubMed
    Score: 0.206
  89. Hormonal regulation of catechol-O-methyl transferase activity in women with uterine leiomyomas. Fertil Steril. 2006 Jul; 86(1):259-62.
    View in: PubMed
    Score: 0.204
  90. Gene therapy and uterine leiomyoma: a review. Hum Reprod Update. 2006 Jul-Aug; 12(4):385-400.
    View in: PubMed
    Score: 0.202
  91. Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Investig. 2006 Feb; 13(2):136-44.
    View in: PubMed
    Score: 0.200
  92. Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am J Obstet Gynecol. 2004 Nov; 191(5):1621-31.
    View in: PubMed
    Score: 0.183
  93. Regulatory roles of NAMPT and NAD+ metabolism in uterine leiomyoma progression: Implications for ECM accumulation, stemness, and microenvironment. Redox Biol. 2024 Dec; 78:103411.
    View in: PubMed
    Score: 0.183
  94. Surgical myomectomy followed by oral Myfembree vs standard of care (SOUL trial): Study protocol for a randomized control trial. PLoS One. 2024; 19(7):e0306053.
    View in: PubMed
    Score: 0.179
  95. Multiomic analysis of uterine leiomyomas in self-described Black and White women: molecular insights into health disparities. Am J Obstet Gynecol. 2024 Sep; 231(3):321.e1-321.e11.
    View in: PubMed
    Score: 0.177
  96. Management of Uterine Fibroids and Sarcomas: The Palermo Position Paper. Gynecol Obstet Invest. 2024; 89(2):73-86.
    View in: PubMed
    Score: 0.174
  97. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study. Am J Obstet Gynecol. 2024 02; 230(2):237.e1-237.e11.
    View in: PubMed
    Score: 0.170
  98. Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women. Nutrients. 2023 Jan 09; 15(2).
    View in: PubMed
    Score: 0.161
  99. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. Lancet. 2022 09 17; 400(10356):896-907.
    View in: PubMed
    Score: 0.158
  100. Human Myometrial and Uterine Fibroid Stem Cell-Derived Organoids for Intervening the Pathophysiology of Uterine Fibroid. Reprod Sci. 2022 09; 29(9):2607-2619.
    View in: PubMed
    Score: 0.154
  101. Adverse childhood experiences and health-related quality of life among women undergoing hysterectomy for uterine leiomyoma. Am J Obstet Gynecol. 2022 08; 227(2):351-353.e5.
    View in: PubMed
    Score: 0.154
  102. A Call-to-Action for Clinicians to Implement Evidence-Based Best Practices When Caring for Women with Uterine Fibroids. Reprod Sci. 2022 04; 29(4):1188-1196.
    View in: PubMed
    Score: 0.152
  103. Simvastatin inhibits stem cell proliferation in human leiomyoma via TGF-ß3 and Wnt/ß-Catenin pathways. J Cell Mol Med. 2022 03; 26(5):1684-1698.
    View in: PubMed
    Score: 0.151
  104. Simvastatin modulates estrogen signaling in uterine leiomyoma via regulating receptor palmitoylation, trafficking and degradation. Pharmacol Res. 2021 10; 172:105856.
    View in: PubMed
    Score: 0.147
  105. The role of endocrine-disrupting chemicals in uterine fibroid pathogenesis. Curr Opin Endocrinol Diabetes Obes. 2020 12; 27(6):380-387.
    View in: PubMed
    Score: 0.140
  106. Summary of the Proceedings of the Basic Science of Uterine Fibroids Meeting: New Developments February 28, 2020. F S Sci. 2021 02; 2(1):88-100.
    View in: PubMed
    Score: 0.139
  107. Non-hormonal mediators of uterine fibroid growth. Curr Opin Obstet Gynecol. 2020 10; 32(5):361-370.
    View in: PubMed
    Score: 0.138
  108. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. Obstet Gynecol. 2020 06; 135(6):1313-1326.
    View in: PubMed
    Score: 0.135
  109. Activation of ß-Catenin Signaling and its Crosstalk With Estrogen and Histone Deacetylases in Human Uterine Fibroids. J Clin Endocrinol Metab. 2020 04 01; 105(4).
    View in: PubMed
    Score: 0.133
  110. The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor. J Clin Endocrinol Metab. 2020 03 01; 105(3).
    View in: PubMed
    Score: 0.132
  111. Uterine fibroids in menopause and perimenopause. Menopause. 2020 02; 27(2):238-242.
    View in: PubMed
    Score: 0.132
  112. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. N Engl J Med. 2020 01 23; 382(4):328-340.
    View in: PubMed
    Score: 0.132
  113. Introduction of Somatic Mutation in MED12 Induces Wnt4/ß-Catenin and Disrupts Autophagy in Human Uterine Myometrial Cell. Reprod Sci. 2020 03; 27(3):823-832.
    View in: PubMed
    Score: 0.131
  114. Neurotrimin: a novel neural cell adhesion molecule correlating with uterine fibroid phenotype. Fertil Steril. 2020 01; 113(1):83-84.
    View in: PubMed
    Score: 0.131
  115. Myometrial progesterone hyper-responsiveness associated with increased risk of human uterine fibroids. BMC Womens Health. 2019 07 09; 19(1):92.
    View in: PubMed
    Score: 0.127
  116. H19 lncRNA identified as a master regulator of genes that drive uterine leiomyomas. Oncogene. 2019 07; 38(27):5356-5366.
    View in: PubMed
    Score: 0.125
  117. Targeting the transforming growth factor-ß pathway: a novel mechanism of ulipristal acetate action against uterine fibroids. Fertil Steril. 2019 04; 111(4):683-684.
    View in: PubMed
    Score: 0.124
  118. Vitamin D, a promising natural compound with anti-uterine fibroid characteristics. Fertil Steril. 2019 02; 111(2):268-269.
    View in: PubMed
    Score: 0.122
  119. 1,25 Dihydroxyvitamin D3 Enhances the Antifibroid Effects of Ulipristal Acetate in Human Uterine Fibroids. Reprod Sci. 2019 06; 26(6):812-828.
    View in: PubMed
    Score: 0.122
  120. Hypovitaminosis D exacerbates the DNA damage load in human uterine fibroids, which is ameliorated by vitamin D3 treatment. Acta Pharmacol Sin. 2019 Jul; 40(7):957-970.
    View in: PubMed
    Score: 0.121
  121. Mediator Kinase Disruption in MED12-Mutant Uterine Fibroids From Hispanic Women of South Texas. J Clin Endocrinol Metab. 2018 11 01; 103(11):4283-4292.
    View in: PubMed
    Score: 0.121
  122. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2018 11; 132(5):1252-1264.
    View in: PubMed
    Score: 0.121
  123. Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women. J Womens Health (Larchmt). 2018 11; 27(11):1359-1367.
    View in: PubMed
    Score: 0.120
  124. A Preliminary Study: Human Fibroid Stro-1+/CD44+ Stem Cells Isolated From Uterine Fibroids Demonstrate Decreased DNA Repair and Genomic Integrity Compared to Adjacent Myometrial Stro-1+/CD44+ Cells. Reprod Sci. 2019 05; 26(5):619-638.
    View in: PubMed
    Score: 0.118
  125. Non-coding RNAs: an important regulatory mechanism in pathogenesis of uterine fibroids. Fertil Steril. 2018 05; 109(5):802-803.
    View in: PubMed
    Score: 0.117
  126. Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19. J Biol Chem. 2018 03 30; 293(13):4870-4882.
    View in: PubMed
    Score: 0.115
  127. Uterine Fibroids: Bridging Genomic Defects and Chronic Inflammation. Semin Reprod Med. 2017 11; 35(6):494-498.
    View in: PubMed
    Score: 0.113
  128. Oxidative stress: a key regulator of leiomyoma cell survival. Fertil Steril. 2017 06; 107(6):1387-1394.e1.
    View in: PubMed
    Score: 0.109
  129. Berberine Inhibits Uterine Leiomyoma Cell Proliferation via Downregulation of Cyclooxygenase 2 and Pituitary Tumor-Transforming Gene 1. Reprod Sci. 2017 07; 24(7):1005-1013.
    View in: PubMed
    Score: 0.105
  130. Endocrine-disrupting chemicals and uterine fibroids. Fertil Steril. 2016 09 15; 106(4):967-77.
    View in: PubMed
    Score: 0.104
  131. Role of vitamin D in uterine fibroid biology. Fertil Steril. 2015 Sep; 104(3):698-706.
    View in: PubMed
    Score: 0.096
  132. Stro-1/CD44 as putative human myometrial and fibroid stem cell markers. Fertil Steril. 2015 Jul; 104(1):225-34.e3.
    View in: PubMed
    Score: 0.095
  133. Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy. Mol Med. 2015 Apr 13; 21:242-56.
    View in: PubMed
    Score: 0.094
  134. Novel effects of simvastatin on uterine fibroid tumors: in vitro and patient-derived xenograft mouse model study. Am J Obstet Gynecol. 2015 Aug; 213(2):196.e1-8.
    View in: PubMed
    Score: 0.094
  135. Berberine inhibits the proliferation of human uterine leiomyoma cells. Fertil Steril. 2015 Apr; 103(4):1098-106.
    View in: PubMed
    Score: 0.093
  136. Nicotinamide adenine dinucleotide phosphate oxidase is differentially regulated in normal myometrium versus leiomyoma. Reprod Sci. 2014 Sep; 21(9):1145-52.
    View in: PubMed
    Score: 0.087
  137. Uterine fibroids are characterized by an impaired antioxidant cellular system: potential role of hypoxia in the pathophysiology of uterine fibroids. J Assist Reprod Genet. 2013 Jul; 30(7):969-74.
    View in: PubMed
    Score: 0.083
  138. 1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab. 2011 Apr; 96(4):E754-62.
    View in: PubMed
    Score: 0.071
  139. Gene therapy of benign gynecological diseases. Adv Drug Deliv Rev. 2009 Aug 10; 61(10):822-35.
    View in: PubMed
    Score: 0.063
  140. Potential nonhormonal therapeutics for medical treatment of leiomyomas. Semin Reprod Med. 2004 May; 22(2):121-30.
    View in: PubMed
    Score: 0.044
  141. Targeting Hedgehog Pathway and DNA Methyltransferases in Uterine Leiomyosarcoma Cells. Cells. 2020 12 31; 10(1).
    View in: PubMed
    Score: 0.035
  142. Vitamin D3 Ameliorates DNA Damage Caused by Developmental Exposure to Endocrine Disruptors in the Uterine Myometrial Stem Cells of Eker Rats. Cells. 2020 06 12; 9(6).
    View in: PubMed
    Score: 0.034
  143. Simvastatin potently induces calcium-dependent apoptosis of human leiomyoma cells. J Biol Chem. 2014 Dec 19; 289(51):35075-86.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.